Talking about the vaccine, Professor Sanjeev Krishna, of St George's University of London's Institute for Infection and Immunity, said, "An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively."
Adding, "We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola. We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments."
The first known human cases of Ebola occurred in 1976 during two simultaneous outbreaks in Sudan and the Democratic Republic of Congo, which sickened more than 600 people, according to the World Health Organization.
This vaccine can be really useful for a country like India, who did not see an outbreak of Ebola. Though an Indian national returning from Liberia did test positive for the deadly virus and was quarantined at a special facility at Delhi airport.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebola virus outbreaks in the past.
The study was published in journal PLOS Medicine. (ANI)